Wood G W, Neff J R
J Natl Cancer Inst. 1978 Sep;61(3):715-8.
B-lymphocytes were quantitated in mononuclear cell suspensions derived from the peripheral blood of patients with various nonlymphoreticular cancers. The method used was anti-IgM and anti-IgD membrane immunofluorescence. The mean percentage of circulating B-lymphocytes in 78 cancer patients tested was 5.3 +/- 4.6 with a range of 0--18%. Those values were compared with a mean of 9.4 +/- 4.0 and a range of 3--20% for 46 apparently normal individuals. The difference was highly significant (P less than or equal to 0.001). The mean percentage of B-cells in cell suspensions from 43 patients that were tested prior to treatment was 5.8 +/- 4.8 with a range of 0--18%. Very low values were observed both in the presence and absence of therapy, and a correlation with stage of disease could not be established. The low values were associated with decreased T-cell numbers and significantly increased monocyte levels. The fact that those values were significantly lower than have been reported previously for cancer patients was discussed as was the identity of the cells that previously had been counted as B-lymphocytes.
采用抗IgM和抗IgD膜免疫荧光法,对各种非淋巴细胞性癌症患者外周血来源的单核细胞悬液中的B淋巴细胞进行定量分析。在接受检测的78例癌症患者中,循环B淋巴细胞的平均百分比为5.3±4.6,范围为0%-18%。将这些数值与46例表面健康个体的平均数值9.4±4.0(范围为3%-20%)进行比较。差异具有高度显著性(P≤0.001)。在治疗前接受检测的43例患者的细胞悬液中,B细胞的平均百分比为5.8±4.8,范围为0%-18%。无论是否接受治疗,均观察到极低的数值,且无法确定其与疾病分期的相关性。这些低数值与T细胞数量减少和单核细胞水平显著升高有关。文中讨论了这些数值显著低于先前报道的癌症患者数值这一事实,以及先前被计为B淋巴细胞的细胞的身份。